Serono, Inc. is a leader in the US biotechnology arena, integrating cutting-edge science with unparalleled patient support systems to improve people’s lives. Through its focus on specialized therapeutic areas, including reproductive health, metabolic endocrinology and neurology, as well as oncology as an emerging area of expertise, Serono, Inc. is committed to discovering and developing innovative products that address unmet medical needs.
As the US affiliate of Serono S.A., a global biotechnology leader headquartered in Geneva, Switzerland, Serono, Inc. is an integral part of driving the growth and success of the company’s global business. In 2004, North American product sales accounted for approximately 40% of worldwide revenue.
Serono, Inc. employs more than 450 people at its world-class research and commercial facility in Rockland, MA, including more than 90 scientists dedicated to understanding diseases and developing the treatments of the future.
The company’s U.S. products are Rebif® (interferon beta-1a), Novantrone® (mitoxantrone for injection concentrate), Gonal-f® (follitropin alfa for injection), Luveris® (lutropin alfa for injection), Ovidrel® (choriogonadotropin alfa injection), Crinone 8%® (progesterone gel), Cetrotide® (cetrorelix acetate for injection), Serostim® [somatropin (rDNA origin) for injection], Saizen® [somatropin (rDNA origin) for injection] and Zorbtive™ [somatropin (rDNA origin) for injection].
In 2004, Serono SA achieved worldwide revenues of $2.4 billion, and a net income of $494.2m, making it the third largest biotech company in the world. The company operates in 45 countries, and its products are sold in over 90 countries. Bearer shares of Serono S.A., the holding company, are traded on the virt-x (SEO) and its American Depositary Shares are traded on the New York Stock Exchange (SRA).